Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A1EWVY8
Tue, 17.09.2024
Formycon AG
Press Release // September 17, 2024
Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna
Planegg-Martinsried – Formycon AG (FWB: FYB) will present clinical study data of its ustekinumab biosimilar candidate FYB202 at this year's European Academy of Derma [ … ]
Tue, 17.09.2024
Formycon AG
Press Release // September 17, 2024
Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna
Planegg-Martinsried – Formycon AG (FWB: FYB) will present clinical study data of its ustekinumab biosimilar candidate FYB202 at this year's European Academy of Derma [ … ]
Mon, 19.08.2024
Formycon AG
Company Name:
Formycon AG
ISIN:
DE000A1EWVY8
Reason for the research:
H1/24 results
Recommendation:
Buy
from:
19.08.2024
Target price:
€80
Target price on sight of:
12 months
Last rating change:
-
Analyst:
Simon Scholes
First Berlin Equity Research has published a research update on Formycon AG (ISIN: DE000A1EWVY8). Analy [ … ]
Tue, 13.08.2024
Formycon AG
Press Release // August 13, 2024
Formycon reports a strong first half-year with multiple milestones achieved
Successful business development characterized by key operational, clinical, and regulatory milestones
Group revenue and EBITDA in line with expectations
Operating results of FYB201 in the first half of the year significantly exceeded ex [ … ]
Wed, 07.08.2024
Formycon AG
Press Release // August 7, 2024
Formycon invites to conference call on 2024 half-year results and announces participation in international investor conferences
Planegg-Martinsried, Germany – Formycon AG (FWB: FYB) today announced details for the financial and earnings conference call for the first half of the 2024 fiscal year on August 13, 2 [ … ]
Tue, 06.08.2024
Formycon AG
Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014
Formycon AG increases its outlook for the 2024 fiscal year
Planegg-Martinsried, Germany, August 06, 2024 – Formycon AG (ISIN: DE000A1EWVY8 / WKN: A1EWVY) (“Company”) has today decided, based on the preliminary half-year figures, to raise its guidance for t [ … ]
Tue, 30.07.2024
Formycon AG
Press Release // July 30, 2024
Formycon announces start of clinical phase III trial for Keytruda® biosimilar candidate FYB206
Phase III “Lotus” trial compares safety and efficacy of FYB206 with reference drug Keytruda®1 (pembrolizumab)
The “Lotus” trial will involve the treatment of around 500 randomized NSCLC2 patients in various countries [ … ]
Fri, 26.07.2024
Formycon AG
Press Release // July 26, 2024
Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 (Ustekinumab), a biosimilar candidate to Stelara®
Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommends approval of FYB202 for the treatment of severe inflammatory diseases in the fields of gastroente [ … ]
Fri, 26.07.2024
Formycon AG
Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014
Stelara® Biosimilar Candidate FYB202 (Ustekinumab) receives positive CHMP opinion from EMA
Planegg-Martinsried, Germany, July 26, 2024 – Formycon AG (FSE: FYB, "Formycon“) announces that the Committee for Medicinal Products for Human Use („CHMP“) of the Eu [ … ]
Mon, 01.07.2024
Formycon AG
Press Release // July 01, 2024
Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2)
Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) and its licensing partner Klinge Biopharma GmbH ("Klinge") jointly announce that the U.S. Food and Drug Administration ("FDA") approved FYB203/AHZA [ … ]